https://www.nobelprize.org/prizes/medicine/2018/press-release/

Buchbinder, E. I., & Desai, A. (2016). CTLA-4 and PD-1 pathways: Similarities, differences, and implications of their inhibition. American Journal Of Clinical Oncology, 39(1), 98–106. https://doi.org/10.1097/COC.0000000000000239

Article  PubMed  PubMed Central  CAS  Google Scholar 

Lu, L., Zhan, M., Li, X. Y., Zhang, H., Dauphars, D. J., Jiang, J., Yin, H., Li, S. Y., Luo, S., Li, Y., & He, Y. W. (2022). Clinically approved combination immunotherapy: Current status, limitations, and future perspective. Curr Res Immunol, 3, 118–127. https://doi.org/10.1016/j.crimmu.2022.05.003

Article  PubMed  PubMed Central  CAS  Google Scholar 

Mittendorf, E. A., Burgers, F., Haanen, J., & Cascone, T. (2022). Neoadjuvant immunotherapy: Leveraging the immune system to treat early-stage disease. American Society of Clinical Oncology Educational Book, 42, 1–15. https://doi.org/10.1200/EDBK_349411

Article  PubMed  Google Scholar 

Jin, Y., Wei, J., Weng, Y., Feng, J., Xu, Z., Wang, P., Cui, X., Chen, X., Wang, J., & Peng, M. (2022). Adjuvant therapy with PD1/PDL1 inhibitors for human cancers: A systematic review and meta-analysis. Frontiers In Oncology, 12, 732814. https://doi.org/10.3389/fonc.2022.732814

Article  PubMed  PubMed Central  CAS  Google Scholar 

Cercek, A., Lumish, M., Sinopoli, J., Weiss, J., Shia, J., Lamendola-Essel, M., El Dika, I. H., Segal, N., Shcherba, M., Sugarman, R., Stadler, Z., Yaeger, R., Smith, J. J., Rousseau, B., Argiles, G., Patel, M., Desai, A., Saltz, L. B., Widmar, M., … Diaz, L. A., Jr. (2022). PD-1 Blockade in mismatch repair-deficient, locally advanced rectal cancer. New England Journal Of Medicine, 386(25), 2363–2376. https://doi.org/10.1056/NEJMoa2201445

Article  PubMed  CAS  Google Scholar 

Goodman, A. M., Piccioni, D., Kato, S., Boichard, A., Wang, H. Y., Frampton, G., Lippman, S. M., Connelly, C., Fabrizio, D., Miller, V., Sicklick, J. K., & Kurzrock, R. (2018). Prevalence of PDL1 amplification and preliminary response to immune checkpoint blockade in solid tumors. JAMA Oncology, 4(9), 1237–1244. https://doi.org/10.1001/jamaoncol.2018.1701

Article  PubMed  PubMed Central  Google Scholar 

Goodman, A. M., Kato, S., Bazhenova, L., Patel, S. P., Frampton, G. M., Miller, V., Stephens, P. J., Daniels, G. A., & Kurzrock, R. (2017). Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers. Molecular Cancer Therapeutics, 16(11), 2598–2608. https://doi.org/10.1158/1535-7163.MCT-17-0386

Article  PubMed  PubMed Central  CAS  Google Scholar 

Patel, S. P., & Kurzrock, R. (2015). PD-L1 Expression as a predictive biomarker in cancer immunotherapy. Molecular Cancer Therapeutics, 14(4), 847–856. https://doi.org/10.1158/1535-7163.MCT-14-0983

Article  PubMed  CAS  Google Scholar 

Bevins, N. J., Okamura, R., Montesion, M., Adashek, J. J., Goodman, A. M., & Kurzrock, R. (2022). Tumor infiltrating lymphocyte expression of PD-1 predicts response to anti-PD-1/PD-L1 immunotherapy. J Immunother Precis Oncol, 5(4), 90–97. https://doi.org/10.36401/JIPO-22-9

Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., Leming, P. D., Spigel, D. R., Antonia, S. J., Horn, L., Drake, C. G., Pardoll, D. M., Chen, L., Sharfman, W. H., Anders, R. A., … Sznol, M. (2012). Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. New England Journal Of Medicine, 366(26), 2443–2454. https://doi.org/10.1056/NEJMoa1200690

Article  PubMed  CAS  Google Scholar 

Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., Wong, F., Azad, N. S., Rucki, A. A., Laheru, D., Donehower, R., Zaheer, A., Fisher, G. A., Crocenzi, T. S., Lee, J. J., … Diaz, L. A., Jr. (2017). Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science, 357(6349), 409–413. https://doi.org/10.1126/science.aan6733

Article  PubMed  PubMed Central  CAS  Google Scholar 

Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., Biedrzycki, B., Donehower, R. C., Zaheer, A., Fisher, G. A., Crocenzi, T. S., Lee, J. J., Duffy, S. M., Goldberg, R. M., de la Chapelle, A., … Diaz, L. A., Jr. (2015). PD-1 Blockade in tumors with mismatch-repair deficiency. New England Journal Of Medicine, 372(26), 2509–2520. https://doi.org/10.1056/NEJMoa1500596

Article  PubMed  CAS  Google Scholar 

Jardim, D. L., Goodman, A., de Melo Gagliato, D., & Kurzrock, R. (2021). The challenges of tumor mutational burden as an immunotherapy biomarker. Cancer Cell, 39(2), 154–173. https://doi.org/10.1016/j.ccell.2020.10.001

Article  PubMed  CAS  Google Scholar 

Thompson, J. A., Schneider, B. J., Brahmer, J., Achufusi, A., Armand, P., Berkenstock, M. K., Bhatia, S., Budde, L. E., Chokshi, S., Davies, M., Elshoury, A., Gesthalter, Y., Hegde, A., Jain, M., Kaffenberger, B. H., Lechner, M. G., Li, T., Marr, A., McGettigan, S., McPherson, J., Medina, T., Mohindra, N. A., Olszanski, A. J., Oluwole, O., Patel, S. P., Patil, P., Reddy, S., Ryder, M., Santomasso, B., Shofer, S., Sosman, J. A., Wang, Y., Zaha, V. G., Lyons, M., Dwyer, M., & Hang, L. (2022). Management of immunotherapy-related toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology. Journal Of The National Comprehensive Cancer Network, 20(4), 387–405. https://doi.org/10.6004/jnccn.2022.0020

Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Rutkowski, P., Lao, C. D., Cowey, C. L., Schadendorf, D., Wagstaff, J., Dummer, R., Ferrucci, P. F., Smylie, M., Hogg, D., Hill, A., Marquez-Rodas, I., Haanen, J., Guidoboni, M., Maio, M., Schoffski, P., … Wolchok, J. D. (2019). Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. New England Journal Of Medicine, 381(16), 1535–1546. https://doi.org/10.1056/NEJMoa1910836

Article  PubMed  CAS  Google Scholar 

Petrelli, F., Signorelli, D., Ghidini, M., Ghidini, A., Pizzutilo, E. G., Ruggieri, L., Cabiddu, M., Borgonovo, K., Dognini, G., Brighenti, M., De Toma, A., Rijavec, E., Garassino, M. C., Grossi, F., & Tomasello, G. (2020). Association of steroids use with survival in patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis. Cancers (Basel), 12(3). https://doi.org/10.3390/cancers12030546

Renner, A., Burotto, M., & Rojas, C. (2019). Immune checkpoint inhibitor dosing: Can we go lower without compromising clinical efficacy? J Glob Oncol, 5, 1–5. https://doi.org/10.1200/JGO.19.00142

Article  PubMed  Google Scholar 

Champiat, S., Dercle, L., Ammari, S., Massard, C., Hollebecque, A., Postel-Vinay, S., Chaput, N., Eggermont, A., Marabelle, A., Soria, J. C., & Ferte, C. (2017). Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1/PD-L1. Clinical Cancer Research, 23(8), 1920–1928. https://doi.org/10.1158/1078-0432.CCR-16-1741

Article  PubMed  CAS  Google Scholar 

Kato, S., Goodman, A., Walavalkar, V., Barkauskas, D. A., Sharabi, A., & Kurzrock, R. (2017). Hyperprogressors after immunotherapy: Analysis of genomic alterations associated with accelerated growth rate. Clinical Cancer Research, 23(15), 4242–4250. https://doi.org/10.1158/1078-0432.CCR-16-3133

Article  PubMed  PubMed Central  CAS  Google Scholar 

Adashek, J. J., Subbiah, I. M., Matos, I., Garralda, E., Menta, A. K., Ganeshan, D. M., & Subbiah, V. (2020). Hyperprogression and immunotherapy: Fact, fiction, or alternative fact? Trends Cancer, 6(3), 181–191. https://doi.org/10.1016/j.trecan.2020.01.005

Article  PubMed  PubMed Central  CAS  Google Scholar 

Adashek, J. J., Kato, S., Ferrara, R., Lo Russo, G., & Kurzrock, R. (2020). Hyperprogression and immune checkpoint inhibitors: Hype or progress? The Oncologist, 25(2), 94–98. https://doi.org/10.1634/theoncologist.2019-0636

Article  PubMed  Google Scholar 

Wolchok, J. D., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Rutkowski, P., Lao, C. D., Cowey, C. L., Schadendorf, D., Wagstaff, J., Dummer, R., Ferrucci, P. F., Smylie, M., Butler, M. O., Hill, A., Marquez-Rodas, I., Haanen, J., Guidoboni, M., Maio, M., Schoffski, P., … Hodi, F. S. (2022). Long-term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma. Journal Of Clinical Oncology, 40(2), 127–137. https://doi.org/10.1200/JCO.21.02229

Article  PubMed  CAS  Google Scholar 

Motzer, R. J., McDermott, D. F., Escudier, B., Burotto, M., Choueiri, T. K., Hammers, H. J., Barthelemy, P., Plimack, E. R., Porta, C., George, S., Powles, T., Donskov, F., Gurney, H., Kollmannsberger, C. K., Grimm, M. O., Barrios, C., Tomita, Y., Castellano, D., Grunwald, V., … Tannir, N. M. (2022). Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma. Cancer, 128(11), 2085–2097. https://doi.org/10.1002/cncr.34180

Article  PubMed  CAS  Google Scholar 

Brahmer, J. R., Lee, J. S., Ciuleanu, T. E., Bernabe Caro, R., Nishio, M., Urban, L., Audigier-Valette, C., Lupinacci, L., Sangha, R., Pluzanski, A., Burgers, J., Mahave, M., Ahmed, S., Schoenfeld, A. J., Paz-Ares, L. G., Reck, M., Borghaei, H., O’Byrne, K. J., Gupta, R. G., … Ramalingam, S. S. (2023). Five-year survival outcomes with nivolumab plus ipilimumab versus chemotherapy as first-line treatment for metastatic non-small-cell lung cancer in CheckMate 227. Journal Of Clinical Oncology, 41(6), 1200–1212. https://doi.org/10.1200/JCO.22.01503

Article  PubMed  CAS  Google Scholar 

https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-pembrolizumab-first-tissuesite-agnostic-indication

Andre, T., Berton, D., Curigliano, G., Sabatier, R., Tinker, A. V., Oaknin, A., Ellard, S., de Braud, F., Arkenau, H. T., Trigo, J., Gravina, A., Kristeleit, R., Moreno, V., Abdeddaim, C., Vano, Y. A., Samouelian, V., Miller, R., Boni, V., Torres, A. A., … Banerjee, S. (2023). Antitumor activity and safety of dostarlimab monotherapy in patients with mismatch repair deficient solid tumors: A nonrandomized controlled trial. JAMA Network Open, 6(11), e2341165. https://doi.org/10.1001/jamanetworkopen.2023.41165